Cytosorbents Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 129

Employees

  • Stock Symbol
  • CTSO

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.35
  • (As of Friday Closing)

Cytosorbents General Information

Description

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

Contact Information

Formerly Known As
Medasorb Technologies, Advanced Renal Technologies, Gilder Enterprises, RenalTech International
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 305 College Road East
  • Princeton, NJ 08540
  • United States
+1 (732)
Primary Industry
Surgical Devices
Stock Exchange
NAS
Corporate Office
  • 305 College Road East
  • Princeton, NJ 08540
  • United States
+1 (732)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cytosorbents Stock Performance

As of 20-Nov-2026, Cytosorbents’s stock price is $4.35. Its current market cap is $13.1M with 3.15M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.35 $5.13 $2.84 - $17.00 $13.1M 3.15M 37.1K -$5.62

Cytosorbents Financials Summary

As of 30-Sep-2026, Cytosorbents has a trailing 12-month revenue of $37.5M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 37,302 59,745 71,127 67,593
Revenue 37,458 37,063 35,595 31,085
EBITDA (12,631) (4,356) (19,267) (27,879)
Net Income (17,502) (8,198) (20,719) (29,247)
Total Assets 37,160 44,182 47,372 52,956
Total Debt 29,574 29,111 26,893 18,313
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cytosorbents Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cytosorbents‘s full profile, request access.

Request a free trial

Cytosorbents Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive ca
Surgical Devices
Princeton, NJ
129 As of 2025

Martinez, CA
 

Lakewood, CO
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cytosorbents Competitors (4)

One of Cytosorbents’s 4 competitors is ExThera Medical, a Venture Capital-Backed company based in Martinez, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ExThera Medical Venture Capital-Backed Martinez, CA
TerumoBCT Formerly PE-Backed Lakewood, CO
Kimal Formerly Accelerator/Incubator backed Worcester, United Kingdom
PreAnalytiX Corporate Backed or Acquired Hombrechtikon, Switzerland
To view Cytosorbents’s complete competitors history, request access »

Cytosorbents Patents

Cytosorbents Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3237831-A1 Improved cancer immunotherapy treatments Pending 29-Nov-2021
EP-4440657-A1 Improved cancer immunotherapy treatments Pending 29-Nov-2021
EP-4440657-A4 Improved cancer immunotherapy treatments Pending 29-Nov-2021
US-20250009951-A1 Improved cancer immunotherapy treatments Pending 29-Nov-2021
WO-2023097334-A1 Improved cancer immunotherapy treatments Inactive 29-Nov-2021 A61M1/36
To view Cytosorbents’s complete patent history, request access »

Cytosorbents Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cytosorbents Acquisitions (1)

Cytosorbents’s most recent deal was a Merger/Acquisition with Gilder Enterprises. The deal was made on 30-Jun-2006.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gilder Enterprises 30-Jun-2006 Merger/Acquisition Internet Service Providers
To view Cytosorbents’s complete acquisitions history, request access »

Cytosorbents ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

39.11 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Healthcare

Industry

of 590

Rank

Percentile

Medical Devices

Subindustry

of 209

Rank

Percentile

To view Cytosorbents’s complete esg history, request access »

Cytosorbents FAQs

  • When was Cytosorbents founded?

    Cytosorbents was founded in 1997.

  • Where is Cytosorbents headquartered?

    Cytosorbents is headquartered in Princeton, NJ.

  • What is the size of Cytosorbents?

    Cytosorbents has 129 total employees.

  • What industry is Cytosorbents in?

    Cytosorbents’s primary industry is Surgical Devices.

  • Is Cytosorbents a private or public company?

    Cytosorbents is a Public company.

  • What is Cytosorbents’s stock symbol?

    The ticker symbol for Cytosorbents is CTSO.

  • What is the current stock price of Cytosorbents?

    As of 20-Nov-2026 the stock price of Cytosorbents is $4.35.

  • What is the current market cap of Cytosorbents?

    The current market capitalization of Cytosorbents is $13.1M.

  • What is Cytosorbents’s current revenue?

    The trailing twelve month revenue for Cytosorbents is $37.5M.

  • Who are Cytosorbents’s competitors?

    ExThera Medical, TerumoBCT, Kimal, and PreAnalytiX are competitors of Cytosorbents.

  • What is Cytosorbents’s annual earnings per share (EPS)?

    Cytosorbents’s EPS for 12 months was -$5.62.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process